AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone

Naturo & Orgo empowering brands through excellence

The company offers customized formulations tailored to align with each brand’s identity and consumer needs

Entero launches ‘HealthEdge’ programme to empower Retail Chemists

Emcure partners with Vidya Balan for Arth supplements,

Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues

Zydus Lifesciences launches ANVIMO

ANVIMO will be available in dosages of 240 mg and 480 mg

Somaiya Vidyavihar University hosts conference on ‘Clinical Translation of Biomaterials for Future Healthcare’

Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar

NURA AI Health Screening Centre Bengaluru celebrates 4th anniversary of transforming lives through early detection

Plans underway to expand screening capacity by 50% for greater accessibility

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines

The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25

Calquence combination approved in US for untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone